Bill

HR 2197

No 340B Savings for Transgender Care Act

119th Congress Introduced by Stephanie Bice and 10 co-sponsors

HR 2197 prohibits using 340B savings for transgender care, impacting providers' funding and potentially limiting access to healthcare for transgender individuals.

Introduced in House

WeVote Research Nonpartisan

Bill Summary · HR 2197

Summary of HR 2197: No 340B Savings for Transgender Care Act

Bill Overview

Bill Number: HR 2197
Title: No 340B Savings for Transgender Care Act
Status: Introduced in House
Introduced Date: March 18, 2025
Classification: Bill

Purpose and Intent

The No 340B Savings for Transgender Care Act aims to address the financial implications of the 340B Drug Pricing Program specifically concerning healthcare services for transgender individuals. The bill seeks to ensure that savings generated from the 340B program are not utilized to subsidize or support transgender care services.

Key Provisions

Exclusion of Transgender Care from 340B Savings: The bill proposes that any savings accrued through the 340B program cannot be applied to transgender healthcare services. This means that healthcare providers participating in the 340B program would not be able to use these savings to offset costs associated with transgender-related medical care.
Impact on Healthcare Providers: The legislation would directly affect healthcare providers that offer transgender care services, particularly those that rely on the 340B program for financial support. Providers may need to find alternative funding sources to cover the costs of these services.

Affected Parties

Healthcare Providers: Hospitals and clinics that provide transgender care and participate in the 340B program will be significantly impacted. They may face financial challenges in offering these services without the benefit of 340B savings.
Transgender Individuals: Patients seeking transgender healthcare services may experience reduced access or increased costs as providers adjust to the financial constraints imposed by this legislation.

Legislative Process

Committee Referral: Upon introduction, HR 2197 was referred to the House Committee on Energy and Commerce for further consideration. This committee will review the bill, hold hearings, and may propose amendments before it is brought to the House floor for a vote.

Conclusion

The No 340B Savings for Transgender Care Act represents a significant legislative effort to redefine the financial landscape of transgender healthcare services within the context of the 340B Drug Pricing Program. As the bill progresses through the legislative process, its implications for healthcare providers and transgender individuals will be closely monitored.

Compiled from official sources — confirm details with the bill’s official record.